Myelin basic protein in CSF as indicator of disease activity in multiple sclerosis

Lamers, K.J.B.; Reus, H.P.M. de; Jongen, P.J.H.

doi:10.1191/135245898678909358

Cited by 4 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has long been known that MBP is a potential biomarker of disease activity for MS, as it shows acute CNS myelin damage, although it is not disease-specific. Several studies have found elevated levels of MBP in CSF in MS patients temporarily associated with relapses [87] and detectable up to 5-6 weeks later [88]. Accordingly, patients with RRMS with disease activity showed higher values than progressive MS and stable patients [89].…”

Section: Multiple Sclerosis -Genetics Disease Mechanisms and Clinical...mentioning

confidence: 93%

Biomarkers in Multiple Sclerosis

Ignatova¹

2024

Multiple Sclerosis - Genetics, Disease Mechanisms and Clinical Developments

View full text Add to dashboard Cite

Clinical, biological, and radiological evidence are currently needed to diagnose MS, but lack of preclinical biomarkers hinders the earliest possible diagnosis and treatment. Conventional biomarkers target immunity, blood-brain barrier disruption, demyelination, and neuronal and axonal damage, as well as mitochondrial activity. An increase of specific brain metabolites with 30–40% is registered before detection of MRI lesions in MS. Potential lipid biomarkers are fatty acids, phospholipids, and oxysterols. The role of proteoforms in the pathogenesis of MS was confirmed. Serum neurofilament light chains (sNfL) are currently being studied as a readily available biomarker for prognosis and response to treatment in MS. The sNfL levels reflect ongoing neuroaxonal damage caused by inflammation, and the sNfL levels predict disease activity over the next few years. The retinal nerve fiber layer (RNFL) thinning is reliable as a biomarker of disability worsening. The neutrophil-to-lymphocyte ratio and CRP are also MS biomarkers. The development of rationally targeted therapeutic agents that allow preventive treatment to stop the disease is also delayed without definite biomarkers.

show abstract

Section: Multiple Sclerosis -Genetics Disease Mechanisms and Clinical...mentioning

confidence: 93%

Biomarkers in Multiple Sclerosis

Ignatova¹

2024

Multiple Sclerosis - Genetics, Disease Mechanisms and Clinical Developments

View full text Add to dashboard Cite

show abstract

“…Accordingly, RRMS patients with disease activity show higher values than progressive MS and stable patients [165] . CSF MBP concentrations are also greater when polysymptomatic and severe relapses occur, correlating with EDSS score and MRI activity and decreasing after corticosteroid treatment [168,169] . Zhou et al [170] explored the association between MBP gene variations and MS course in a 5-year prospective study involving 127 patients with CIS, identifying a risk genotype (CT+TT of rs12959006) for the risk of conversion to MS, disability progression and relapses.…”

Section: Myelin Basic Proteinmentioning

confidence: 95%

“…Several studies have found increased CSF levels of MBP in patients with MS, temporally related to relapses [158,159,[165][166][167] and detectable up to 5-6 weeks later [168] . Accordingly, RRMS patients with disease activity show higher values than progressive MS and stable patients [165] .…”

Section: Myelin Basic Proteinmentioning

confidence: 99%

CSF biomarkers in multiple sclerosis: beyond neuroinflammation

Toscano¹,

Patti²

2020

View full text Add to dashboard Cite

For many years, quantifiable biomarkers in neurological diseases have represented a hot topic. In multiple sclerosis (MS), cerebrospinal fluid biomarkers have played a diagnostic role since the introduction of Poser's criteria in 1983, with IgG oligoclonal bands playing a supporting role in an epoch prior to magnetic resonance imaging and a complementary one after the introduction of McDonald criteria in 2001. Nowadays, that supporting role has turned into a main one in substituting for dissemination in time and defining the diagnosis of MS in patients with a first clinical event, according to the 2017 revised McDonald criteria. Possibly kappa free light chains, N-CAM, chitinase 3-like protein 1 and IgM oligoclonal bands, not yet implemented in clinical practice, could similarly gain importance in the near future. Furthermore, the increasing knowledge of molecular mechanisms leading to chronic inflammation has enhanced interest in looking for biomarkers of disease activity, better defining the MS phenotype and patients with highly active disease. Accordingly, myelin proteins, intermediate filaments, metalloproteinases and other molecules involved in the inflammatory cascade, are currently under investigation. Finally, it has long been known that axonal loss occurs from the early phases, leading to a progressive neurological deterioration. Since established criteria to assess treatment failure and transition to progressive forms are still lacking, both treatment response and prognostic biomarkers would be useful to predict MS course, and neurofilaments seem to have this potential. The purpose of this review article was to illustrate biomarkers that have been already validated or require further validation after proving to be useful in exploratory studies and potentially could prove useful in clinical practice in the coming years.

show abstract

“…When oligoclonal IgMs are present, the disease lasts for less than 5 years in 90% of patients, but when IgMs are absent, it lasts for more than 5 years in 60% of patients. (2) Anti-MBPs in CSF are high during relapses in about 90% of patients but vanish during the 6 weeks following onset, relapse treatment appearing to precipitate this event [80,81].…”

Section: Its Is Robust Over Timementioning

confidence: 99%

Intrathecal Immunoglobulin Synthesis in MS—A Complete Reappraisal

Bonnan¹

2016

Trending Topics in Multiple Sclerosis

View full text Add to dashboard Cite

Multiple sclerosis (MS) is characterized by the intrathecal synthesis (ITS) of immunoglobulins (Igs), which, although nonspecific, is the strongest biological marker. Since no specific target has been elucidated, this synthesis is considered to be disease-irrelevant. We demonstrate that this synthesis provides pertinent information about the pathophysiological processes involved. Quantification of ITS is based on an approximation intrinsically underestimating its level and it remains constant in MS, albeit sometimes at a low level. B-cell maturation seems to be initiated within the cervical lymph nodes and B-cells traffic on both sides of the blood-brain barrier by rounds of bidirectional traffic. During this process, they undergo somatic hypermutation, which is the hallmark of antigen-driven antibody maturation, suggesting that most of the ITS is probably directed against as yet unknown targets. Alternatively, examining"non-disease-relevant" ITS in the light of meningeal tertiary lymphoid organs provides new insights into the pathophysiology of MS. Although no specific target has yet been identified in MS, recent developments in the search for targeted antigens point to non-conventional antigens (posttranslationally modified proteins or oxidized products) of which a few are promising for future research.

show abstract

Myelin basic protein in CSF as indicator of disease activity in multiple sclerosis

Cited by 4 publications

References 0 publications

Biomarkers in Multiple Sclerosis

Biomarkers in Multiple Sclerosis

CSF biomarkers in multiple sclerosis: beyond neuroinflammation

Intrathecal Immunoglobulin Synthesis in MS—A Complete Reappraisal

Contact Info

Product

Resources

About